{"id":"commercially-available-aspirin","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Gastrointestinal bleeding or ulceration"},{"rate":"5-10","effect":"Dyspepsia"},{"rate":"2-5","effect":"Nausea"},{"rate":"<1","effect":"Hemorrhagic stroke (at higher doses)"},{"rate":"<1","effect":"Allergic reactions (including bronchospasm in aspirin-sensitive patients)"},{"rate":"1-2","effect":"Renal impairment (chronic use)"}]},"_chembl":{"chemblId":"CHEMBL25","moleculeType":"Small molecule","molecularWeight":"180.16"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aspirin acetylates serine residues on COX-1 and COX-2 enzymes, permanently blocking their catalytic activity. This prevents the synthesis of prostaglandins (which mediate inflammation and pain) and thromboxane A2 (which promotes platelet clumping). The antiplatelet effect is particularly durable because aspirin irreversibly modifies platelet COX-1, and platelets cannot synthesize new enzyme.","oneSentence":"Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to decrease inflammation, pain, and platelet aggregation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:48.587Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myocardial infarction"},{"name":"Ischemic stroke prevention"},{"name":"Transient ischemic attack (TIA) prevention"},{"name":"Coronary artery disease"},{"name":"Mild to moderate pain"},{"name":"Fever"},{"name":"Rheumatoid arthritis and other inflammatory conditions"}]},"trialDetails":[{"nctId":"NCT05650411","phase":"NA","title":"Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM)","status":"NOT_YET_RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2026-03-01","conditions":"Left Main Coronary Artery Stenosis","enrollment":828},{"nctId":"NCT05955365","phase":"PHASE4","title":"Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-12-18","conditions":"Percutaneous Coronary Intervention (PCI), Atrial Fibrillation (AF), Oral Anticoagulation","enrollment":3010},{"nctId":"NCT06312800","phase":"PHASE2","title":"Acamprosate and Methazolamide for Essential Tremor","status":"WITHDRAWN","sponsor":"Henry Ford Health System","startDate":"2016-03","conditions":"Essential Tremor","enrollment":""},{"nctId":"NCT05122780","phase":"PHASE4","title":"Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-07-01","conditions":"Myocardial Infarction With Non-Obstructive Coronary Arteries","enrollment":120},{"nctId":"NCT03119012","phase":"PHASE4","title":"P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold","status":"TERMINATED","sponsor":"Samsung Medical Center","startDate":"2017-04-19","conditions":"Coronary Artery Disease, Stents, Atherosclerosis","enrollment":25},{"nctId":"NCT06084000","phase":"NA","title":"STrategies of Scheduled Drug-coated Balloons (DCB) Versus Conventional DES for the interveNTional Therapy of de Novo Lesions in Large Coronary vESSels (STENTLESS) Trial","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-10-15","conditions":"Drug-coated Balloon, Drug-eluting Stent, De Novo Stenosis","enrollment":2700},{"nctId":"NCT04944615","phase":"NA","title":"To Evaluate Whether IVUS-guided Drug-eluting Stent (DES) Implantation Leads to Better Clinical Outcomes Compared to Conventional Angiography in the Treatment of Chronic Complete Occlusion (CTO) Disease.","status":"RECRUITING","sponsor":"CCRF Inc., Beijing, China","startDate":"2022-10-21","conditions":"Chronic Total Occlusion of Coronary Artery","enrollment":1448},{"nctId":"NCT02273531","phase":"PHASE1","title":"Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-01","conditions":"Healthy","enrollment":24},{"nctId":"NCT00699998","phase":"PHASE3","title":"A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-06","conditions":"Acute Coronary Syndrome","enrollment":9326}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":98,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Commercially-available Aspirin","genericName":"Commercially-available Aspirin","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to decrease inflammation, pain, and platelet aggregation. Used for Acute myocardial infarction, Ischemic stroke prevention, Transient ischemic attack (TIA) prevention.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}